All In Biotech

Drug Trial Radar · NCT00052468

Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube Cancer

A Multi-National Randomized Phase-III GCIG Intergroup-Study Comparing 1st-line Chemotherapy With Gemcitabine/Paclitaxel/Carboplatin vs Paclitaxel/Carboplatin In Previously Untreated Patients With Epithelial Ovarian Cancer FIGO Stages I-IV

Last checked: Nov 19, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,742 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,742

Actual

Start

Aug 2002

Primary completion

Jul 2009

Study completion Jan 2011

Sponsor

Lead sponsor
AGO Study GroupAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Nordic Society of Gynaecological Oncology - Clinical Trials Unit; GERCOR - Multidisciplinary Oncology Cooperative Group
First posted
Jan 27, 2003

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
None
Primary purpose
Treatment
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known whether carboplatin and paclitaxel combined with gemcitabine is more effective than carboplatin and paclitaxel alone in treating ovarian epithelial or fallopian tube cancer. PURPOSE: This randomized phase III trial is studying carboplatin and paclitaxel combined with gemcitabine to see how well it works compared to paclitaxel and carboplatin alone in treating patients who have undergone surgery for ovarian epithelial or fallopian tube cancer.

Conditions

  • Fallopian Tube Cancer
  • Ovarian Cancer

Interventions

  • TCGDrug

  • TCDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall SurvivalTime frame: Whole Study Period

Locations

17 sites in 4 countries. Site status is shown where the registry gives one.

  • Herlev Hospital - University Hospital of Copenhagen

    Copenhagen, Denmark

  • Hotel Dieu de Paris

    Paris, France

  • Zentralkrankenhaus

    Bremen, Germany

  • Evangelisches Krankenhaus

    Düsseldorf, Germany

  • Universitaetsklinikum Essen

    Essen, Germany

  • Staedtische Kliniken Frankfurt am Main - Hoechst

    Frankfurt, Germany

  • Frauenklinik der MHH

    Hanover, Germany

  • Vincentius Krankenhaus

    Karlsruhe, Germany

  • University Hospital Schleswig-Holstein - Kiel Campus

    Kiel, Germany

  • Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg

    Magdeburg, Germany

  • Klinikum Grosshadern der Ludwig-Maximilians Universitaet Muenchen

    Munich, Germany

  • Klinikum Rechts Der Isar - Technische Universitaet Muenchen

    Munich, Germany

  • Klinik und Poliklinik fuer Frauenheilkunde und Geburtshilfe - Universitaetsklinikum Muenster

    Münster, Germany

  • Universitaetsklinikum Tuebingen

    Tübingen, Germany

  • Universitaet Ulm

    Ulm, Germany

  • Dr. Horst-Schmidt-Kliniken

    Wiesbaden, Germany

  • Norwegian Radium Hospital

    Oslo, Norway

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.